Boxes with tablets produced by Novartis AG are located on a pharmacy switch.
Bloomberg | Bloomberg | Getty pictures
The Swiss pharmaceutical company Novartis said on Thursday that his Kisqali breast cancer treatment is the next blockbuster medication within its portfolio, since it will be dependent on his heart failure therapy.
Kisqali's turnover, treated with metastatic breast cancer, rose by 64% worldwide worldwide in the three months to June, the company announced in its sales report in the second quarter. This includes 100% growth in the USA
An increase in the Kisqali turnover in the first quarter of March follows by 56%.
CEO VAS Narasimhan said about a winning call that Kisqali was the medication with the greatest scope for outperformance.
According to the Cancer Agency of the World Health Organization, global breast cancer diagnoses and deaths are predicted around 2050, with 1 out of 20 women being diagnosed worldwide with breast cancer.
This could arise to 3.2 million new cases and 1.1 million deaths per year by 2050 if the current trends are continued, according to the study, higher than 2022 2.3 million new cases and 670,000 deaths.
Narasimhan also quoted Novartis' “Strong Pipeline” of other drugs, including his Pluvicto Prostata Cancer treatment and the Scemblix for chronic myeloid leukemia, of which he said that she was also “on the trail of as a blockbuster”.
“We continue to perform a strong performance at our current starts for Kisqali, Pluvicto and Scemblix and demonstrate the replacement performance in our portfolio,” he added in a explanation that accompanied the results.
The comments come when Novartis tries to shake his best-selling entrreso heart sufficiency, which will be exposed to the US patent course next year. Entresto brought in 7.8 billion US dollars in 2024 and accounted for around 15% of the company's global sales.
On Thursday it is to be expected that generic drug manufacturers will begin with the manufacture of imitator versions of the drug, even though this timeline is subject to “a current IP [intellectual property] and regulatory legal disputes. “
On Wednesday, a US federal judge Novartis' application for an injunction rejected MSN pharmaceuticals from selling a generic version of the drug before the patent has expired.
Entresto's turnover rose in line with the previous three -month period in the second quarter.
“In the short term, it is an important product for us,” said the outgoing chief financial officer Harry Kirsch on Thursday via Entresto.
“We have IP that we defend. If we have succeeded in continuing to defend our appointment, we will have a nice significant advantage every month,” he added.
Overall, Novartis net sales rose by 11% to $ 14.05 billion in the second quarter.
In the meantime, adjusted core income rose by 21% to 5.93 billion US dollars, something over the expected 5.69 billion dollars.
Novartis said that it now expects the core income of the entire year to grow by “low teenagers”, which were previously present from “low double -digit digit”, while it retained its forecast for sales growth in the high individual digits.
The company also announced a stock of up to $ 10 billion, whereby the “trust” is listed in the middle and long-term growth of “trust”.
Comments are closed.